Tag:
cystic fibrosis
Latest Headlines
Latest Headlines
Insmed stock soars after FDA ends hold on key lung drug
The company's stock price skyrocketed nearly 63% to $4.40 per share as of 12:07 p.m. ET after the announcement.
UPDATED: Vertex sizzles with upbeat PhII data on combo therapy for cystic fibrosis
The data indicate that Vertex might have a remedy for treating a large number of the 70,000 people worldwide with CF.
Johns Hopkins researchers find gene tied to CF secondary complication
Variations of the MSRA gene appear to affect whether newborns get a cystic fibrosis-related intestinal blockage known as meconium ileus.
U.K. CF gene therapy trials to test inhaled and viral delivery options
A cadre of U.K. researchers will begin a mid-stage trial later this month for a cystic fibrosis gene therapy delivered to the lungs with a nebulizer. They'll also begin a laboratory trial using a more advanced version of the same drug designed to ride in a modified virus to reach its target.
U.K. green lights study of pioneering gene therapy against cystic fibrosis
Researchers in the U.K. plan to launch a mid-stage clinical trial this month for an inhaled gene therapy to combat cystic fibrosis.
Langer upstart rakes in fresh venture cash for mucus-targeting drugs
An upstart biotech company with intriguing new formulation technologies and a roster of influential backers has rounded up $6.2 million in additional seed capital.
Forest Labs to launch inhaled lung infection drug in Germany
Forest Laboratories ($FRX) says it will use Germany to launch the European Union rollout of Colobreathe, its new dry powder inhalation treatment for cystic fibrosis-related lung infections, by...
One father's heartbreak inspired a $250M quest for a cure
Every new drug ever approved involved years of work by dedicated teams of investigators. In the case of the new cystic fibrosis drug Kalydeco from Vertex ( $VRTX ), the story also includes Boston
How do the 12 priciest drugs in the U.S. stack up?
Last week, Vertex Pharmaceuticals ( $VRTX ) got FDA approval for Kalydeco, the first cystic fibrosis drug to address the disease's cause, rather than just its symptoms. The price tag: $294,000. But as
Vertex backs up pricey new CF drug with co-pay help
Vertex Pharmaceuticals ( $VRTX ) achieved another major milestone with FDA's approval of its cystic fibrosis therapy Kalydeco. The "breakthrough" product is the first to address CF's...
